2-氯-4-醛基噻唑 | 5198-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氯-4-醛基噻唑
• 中文别名: 2-氯-4-噻唑羧醛；2-氯噻唑-4-甲醛
• 英文名称: 2-chlorothiazole-4-carbaldehyde
• 英文别名: 2-Chloro-4-formylthiazole；2-chloro-1,3-thiazole-4-carbaldehyde
• CAS: 5198-79-8
• 化学式: C₄H₂ClNOS
• 分子量: 147.585
• InChiKey: JGIIXKZUXXDKOO-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C (sublm)
• 沸点：
  278.6±32.0 °C(Predicted)
• 密度：
  1.541±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934100090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-formylthiazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-formylthiazole
CAS number: 5198-79-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H2ClNOS
Molecular weight: 147.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-醛基噻唑 、 2,3-二氨基萘-1,4-二酮 在 sodium metabisulfite 作用下， 以 乙二醇二甲醚 为溶剂， 以68%的产率得到2-(2-chlorothiazol-4-yl)-1H-naphtho[2,3-d]imidazole-4,9-dione
  参考文献：
  名称：

  作为 IDO1 抑制剂的新型萘醌衍生物的设计、合成和生物学评价

  摘要：

  吲哚胺 2,3-双加氧酶 1 (IDO1) 介导的色氨酸降解犬尿氨酸途径被确定为治疗癌症的免疫疗法中一个有吸引力的新靶点。在这项研究中，合成、表征和评估了一系列新的萘醌衍生物对 IDO1 的抑制活性，并研究了它们的构效关系。其中，化合物T16、T44、T47、T49、T53和T54显示出有效的IDO1抑制活性，IC 50值介于18和61 nM之间，其效力比正在进行临床试验III评估的INCB024360更有效。此外，化合物T28、T44和T53使大鼠血浆中的犬尿氨酸水平降低 30%–50%。还评估了表现出优异 IDO1 抑制活性的化合物对色氨酸 2,3-双加氧酶 (TDO) 的抑制活性。其中，化合物T28 (IDO1 IC 50  = 120 nM) 显示出有希望的 TDO 抑制 (IC 50 72 nM)，并被鉴定为 IDO1/TDO 双重抑制剂。

  DOI：

  10.1016/j.ejmech.2018.08.013
• 作为产物：
  描述：

  2-氯噻唑 、 哌啶-1-甲醛 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 环己烷 、 丙酮 为溶剂， 反应 2.67h， 以85%的产率得到2-氯-4-醛基噻唑
  参考文献：
  名称：

  一种制备2-氯-1, 3-噻唑-5-甲醛的方法

  摘要：

  本发明公开了一种制备2‑氯‑1,3‑噻唑‑5‑甲醛的方法，方法步骤为：在二异丙基氨基锂存在下，（I）所示的2‑氯噻唑与式（II）所示化合物或式（IV）所示化合物在低温条件下反应制得式（III）所示的2‑氯‑1,3‑噻唑‑5‑甲醛；式（II）中，取代基R1和R2各自独立的选自C1‑C4烷基；式（IV）中，X表示C或O元素。本发明使用二异丙基氨基锂可以在较宽温度范围内以较高产率制备2‑氯‑1,3‑噻唑‑5‑甲醛，且该方法未见文献报道，二异丙基氨基锂的脱氢选择性较好，且不会与羰基发生反应。

  公开号：

  CN109678814B

文献信息

• 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210403457A1

  公开（公告）日：2021-12-30

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na v 1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na v 1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

  结构式（I）的新化合物及其药用盐是Nav1.8通道活性的抑制剂，可能在治疗、预防、管理、改善、控制和抑制由Nav1.8通道活性介导的疾病中有用。本发明的化合物可能在治疗、预防或管理疼痛障碍、咳嗽障碍、急性瘙痒障碍和慢性瘙痒障碍中有用。
• 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
  申请人：Bravi Gianpaolo

  公开号：US20050043390A1

  公开（公告）日：2005-02-24

  Novel anti-viral agents of Formula wherein: A represents OR 1 , NR 1 R 2 , or R 1 wherein R 1 and R 2 are hydrogen, C 1-6 alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R 1 and R 2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R 3 wherein R 3 is C 1-6 alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C 1-6 alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C 1-6 -alkyl; F represents hydrogen, C 1-6 alkyl, aryl or heteroaryl; and G represents hydrogen, C 1-6 alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.

  本发明提供了Formula中的新型抗病毒剂，其中：A代表OR1，NR1R2或R1，其中R1和R2为氢，C1-6烷基，芳基，杂环芳基，芳基烷基或杂环芳基烷基；或者R1和R2与它们所附着的氮原子一起形成一个5或6个成员的饱和环；B代表C（O）R3，其中R3为C1-6烷基，芳基，杂环芳基，芳基烷基或杂环芳基烷基；C代表C1-6烷基，芳基，杂环芳基或杂环基；D代表饱和或不饱和的可选取代的6成员杂环环；E代表氢或C1-6烷基；F代表氢，C1-6烷基，芳基或杂环芳基；G代表氢，C1-6烷基，杂环基烷基，芳基烷基或杂环芳基烷基；以及它们的盐，溶剂合物和酯，提供了它们的制备方法和在HCV治疗中使用的方法。
• 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors
  申请人：Glaxo Group Limited

  公开号：US07259163B2

  公开（公告）日：2007-08-21

  Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.

  本发明提供了Formula中的新型抗病毒剂，其中：A代表OR1、NR1R2或R1，其中R1和R2为氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；或R1和R2与它们连接的氮原子一起形成一个5或6成员饱和环；B代表C（O）R3，其中R3为C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；C代表C1-6烷基、芳基、杂环芳基或杂环烷基；D代表饱和或不饱和的、可选择取代的6成员杂环环；E代表氢或C1-6烷基；F代表氢、C1-6烷基、芳基或杂环芳基；G代表氢、C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；以及它们的盐、溶剂化合物和酯，提供了它们的制备方法和在HCV治疗中使用它们的方法。
• WO2019079519A5
  申请人：——

  公开号：WO2019079519A5

  公开（公告）日：2022-10-07
• PARP7 INHIBITORS AND USES THEREOF
  申请人：[en]ANGEL PHARMACEUTICAL CO., LTD.

  公开号：WO2024149231A1

  公开（公告）日：2024-07-18

  Described herein, inter alia, are PARP7 inhibitors and uses thereof.